Amicus Therapeutics (FOLD) Net Margin (2016 - 2025)
Historic Net Margin for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to 10.24%.
- Amicus Therapeutics' Net Margin rose 149900.0% to 10.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.35%, marking a year-over-year increase of 188600.0%. This contributed to the annual value of 10.62% for FY2024, which is 273400.0% up from last year.
- Amicus Therapeutics' Net Margin amounted to 10.24% in Q3 2025, which was up 149900.0% from 15.79% recorded in Q2 2025.
- Over the past 5 years, Amicus Therapeutics' Net Margin peaked at 10.24% during Q3 2025, and registered a low of 108.31% during Q1 2022.
- Over the past 5 years, Amicus Therapeutics' median Net Margin value was 43.86% (recorded in 2024), while the average stood at 44.76%.
- In the last 5 years, Amicus Therapeutics' Net Margin surged by 480700bps in 2021 and then plummeted by -108200bps in 2022.
- Amicus Therapeutics' Net Margin (Quarter) stood at 101.37% in 2021, then soared by 37bps to 63.41% in 2022, then soared by 54bps to 29.41% in 2023, then skyrocketed by 133bps to 9.85% in 2024, then rose by 4bps to 10.24% in 2025.
- Its Net Margin stands at 10.24% for Q3 2025, versus 15.79% for Q2 2025 and 17.31% for Q1 2025.